Actos

DRUG7 trials

Sponsors

Gilead Sciences, Hoffmann-La Roche, VA Office of Research and Development, The University of Texas Health Science Center at San Antonio

Conditions

Cardiovascular DiseasesDiabetes Mellitus Type 2ESRDPre-DiabetesType 2 DiabetesType 2 Diabetes MellitusWeight, Body

Phase 1

Prevention of Progression of Prediabetes, Obesity and CV Risk

RecruitingNCT06446531

The University of Texas Health Science Center at San AntonioCardiovascular Diseases, Pre-Diabetes, Weight, Body

Start: 2024-09-11End: 2027-07-31Target: 64Updated: 2025-11-12

Phase 2

Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin

CompletedNCT00353587

Gilead SciencesType 2 Diabetes

Start: 2006-05-31End: 2007-11-30Updated: 2015-05-01

A Study of Aleglitazar in Patients With Type 2 Diabetes

CompletedNCT00388518

Hoffmann-La RocheDiabetes Mellitus Type 2

Start: 2006-11-30End: 2008-03-31Updated: 2016-11-02

A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.

CompletedNCT00461006

Hoffmann-La RocheDiabetes Mellitus Type 2

Start: 2007-06-30End: 2008-09-30Updated: 2016-08-01

A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure.

CompletedNCT00461058

Hoffmann-La RocheDiabetes Mellitus Type 2

Start: 2007-05-31End: 2007-12-31Updated: 2016-08-05

Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin

TerminatedNCT00814372

Gilead SciencesType 2 Diabetes Mellitus

Start: 2008-12-31End: 2010-02-28Updated: 2015-04-17

Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2

CompletedNCT02278562

VA Office of Research and DevelopmentESRD

Start: 2014-10-22End: 2017-03-01Updated: 2025-02-06

Related Papers

A randomized controlled pilot trial of anakinra and pioglitazone for protein metabolism in patients on maintenance haemodialysis

Journal of Cachexia Sarcopenia and Muscle2024-01-043 citations

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.

2009-06-08145 citations